AT-Patch (ATP-C130/ATP-C70) vs Lung AI
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent in their application of AI to cardiology, but serve distinct purposes. AT-Patch is designed for continuous, long-term ECG monitoring to detect cardiac arrhythmias, while Lung AI provides real-time, AI-powered ultrasound imaging for immediate diagnosis of cardiac and lung conditions. Therefore, the choice between them depends on whether continuous electrical activity monitoring or real-time anatomical imaging is required.
Choose AT-Patch (ATP-C130/ATP-C70) if…
Choose AT-Patch if you require extended, continuous cardiac monitoring for up to 14 days to detect intermittent arrhythmias or evaluate treatment efficacy. Its comfortable, shower-proof design and integrated AI analysis are ideal for patients needing long-term, non-invasive ECG data collection without frequent intervention.
View AT-Patch (ATP-C130/ATP-C70) →Choose Lung AI if…
Choose Lung AI if you need immediate, real-time diagnostic insights into cardiac and lung conditions at the point of care. This handheld AI ultrasound is best suited for scenarios requiring rapid assessment of issues like pleural effusion, consolidation, or cardiac indicators, empowering healthcare professionals to make critical decisions quickly.
View Lung AI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AT-Patch (ATP-C130/ATP-C70) | Lung AI |
|---|---|---|
| Pricing | N/a | Contact for pricing |
| Deployment | Wearable device for patients; analysis software deployed on-premise at medical institutions. | On-device (integrated with Exo Iris handheld ultrasound device) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AT-Patch (ATP-C130/ATP-C70) | Lung AI |
|---|---|---|
| Tool Name | AT-Patch (ATP-C130/ATP-C70) | Lung AI |
| Company | ATsens Co. | Exo |
| Description | FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection. | A high-performance, handheld ultrasound platform that uses artificial intelligence for imaging and therapeutic applications, empowering healthcare professionals to make critical, real-time decisions. |
| Primary Use Case / Core Function | Continuous ECG monitoring for cardiac arrhythmia detection. | AI-powered handheld ultrasound for smarter cardiac and lung scanning, real-time decision making. |
| AI Capabilities | AT-Report software with AI/machine learning algorithms for ECG analysis. | AI-powered detection of pleural effusion, consolidation/atelectasis, automated AI-based indicators for cardiac conditions, guided image capture, on-device AI processing. |
| Form Factor / Device Type | Wearable ECG monitor (compact and lightweight, 13g). | Handheld ultrasound device. |
Videos
Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Lung AI.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
AT-Patch provides continuous ambulatory ECG monitoring for up to 14 days, ideal for detecting intermittent arrhythmias, with analysis software for physician review. Lung AI offers real-time, handheld ultrasound imaging with AI assistance for immediate diagnostic decisions in lung and cardiac conditions at the point of care.
AT-Patch utilizes a high-performance sensor chip for accurate ECG signal acquisition and AI/machine learning algorithms for enhanced arrhythmia detection, minimizing motion artifact with short-length electrodes. Lung AI's AI-powered detection of pleural effusion, consolidation/atelectasis, and automated cardiac indicators, combined with guided image capture, aims to optimize scan quality and diagnostic confidence.
AT-Patch is well-suited for cardiology, family medicine, and internal medicine practices requiring extended, non-invasive ECG monitoring for patients with suspected arrhythmias. Lung AI is designed for cardiology, emergency medicine, and pulmonology, enabling rapid, real-time diagnostic imaging for acute lung and cardiac conditions at the point of care.
AT-Patch includes the AT-Note smartphone app for live ECG viewing and symptom recording, and AT-Report software for analysis, implying software-based training. Lung AI features guided image capture for optimal scans and offers 'Exo U,' an AI-powered POCUS education and training platform, to support user proficiency.
AT-Patch's AT-Report software, deployed on-premise, generates ECG analysis reports, suggesting potential for integration with institutional EHR systems, though specific mechanisms are not detailed. With Lung AI's on-device AI processing and no mention of external reporting software, the primary method for EHR integration would likely involve manual transfer of images or findings from the device.
AT-Patch's wearable nature for patients and on-premise analysis software suggests a rollout involving patient device distribution and software installation across sites, with benefits realized through streamlined long-term ECG monitoring. Lung AI's handheld, on-device AI processing design allows for rapid deployment and immediate use at the point of care across various sites, potentially offering quick clinical benefits through real-time diagnostic insights.